{"id":"metvix-and-conventional-pdt","safety":{"commonSideEffects":[{"rate":null,"effect":"Phototoxic reaction / erythema"},{"rate":null,"effect":"Burning or stinging at treatment site"},{"rate":null,"effect":"Edema"},{"rate":null,"effect":"Crusting or scaling"},{"rate":null,"effect":"Photosensitivity"}]},"_chembl":{"chemblId":"CHEMBL1628401","moleculeType":"Small molecule","molecularWeight":"657.81"},"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"Metvix (methyl aminolevulinate) is a prodrug that penetrates into dysplastic and malignant skin cells where it is converted to protoporphyrin IX, a photosensitizer. Upon illumination with red light at 630 nm, protoporphyrin IX generates singlet oxygen and free radicals that cause selective destruction of the target tissue. This combination of topical photosensitizer and light activation is known as photodynamic therapy (PDT).","oneSentence":"Metvix is a photosensitizing agent that accumulates in abnormal skin cells and, when activated by light in photodynamic therapy (PDT), generates reactive oxygen species to destroy lesions.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:21:10.556Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Actinic keratosis"},{"name":"Basal cell carcinoma"},{"name":"Bowen's disease"}]},"trialDetails":[{"nctId":"NCT07381972","phase":"PHASE3","title":"Photodynamic Therapy Associated With Sonodynamic Therapy for the Treatment of Nodular Basal Cell Carcinoma","status":"RECRUITING","sponsor":"University of Sao Paulo","startDate":"2025-11-24","conditions":"Nodular Basal Cell Carcinoma of Skin","enrollment":142},{"nctId":"NCT02373371","phase":"PHASE3","title":"Actinic Keratoses Treatment With Metvix® in Combination With Light","status":"COMPLETED","sponsor":"University Hospital, Limoges","startDate":"2015-03-25","conditions":"Actinic Keratoses","enrollment":26},{"nctId":"NCT06545396","phase":"NA","title":"Efficacy And Safety Of Illumination Dose Reduction In Red Light Photodynamic Therapy For Actinic Keratoses","status":"NOT_YET_RECRUITING","sponsor":"Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal","startDate":"2024-08","conditions":"Actinic Keratoses","enrollment":20},{"nctId":"NCT05456334","phase":"NA","title":"New Treatments for Actinic Keratoses of the Scalp","status":"UNKNOWN","sponsor":"Helsinki University Central Hospital","startDate":"2016-03-24","conditions":"Photodamaged Skin, Actinic Keratoses","enrollment":120},{"nctId":"NCT01821391","phase":"PHASE3","title":"Phase 3b Study of Metvix NDL-PDT Versus Metvix c-PDT in Subjects With Actinic Keratoses","status":"COMPLETED","sponsor":"Galderma R&D","startDate":"2013-07","conditions":"Actinic Keratoses","enrollment":131},{"nctId":"NCT01475071","phase":"PHASE3","title":"Intra-individual Comparison of Efficacy and Safety of Metvix® Natural Daylight Photodynamic Therapy Versus Conventional Metvix® Photodynamic Therapy in Subject With Mild Actinic Keratoses","status":"COMPLETED","sponsor":"Galderma R&D","startDate":"2012-03","conditions":"Actinic Keratoses","enrollment":100},{"nctId":"NCT03076892","phase":"NA","title":"Evaluation of Non-inferiority and Tolerability of the Device PHOS-ISTOS","status":"COMPLETED","sponsor":"University Hospital, Lille","startDate":"2016-09","conditions":"Keratosis, Actinic","enrollment":47},{"nctId":"NCT02976727","phase":"PHASE1","title":"Efficacy of Topical Calcipotriol-assisted AFL-PDT in Actinic Keratosis","status":"COMPLETED","sponsor":"Dong-A University","startDate":"2014-05","conditions":"Actinic Dermatosis","enrollment":48},{"nctId":"NCT02670655","phase":"PHASE1","title":"Efficacy of Iontophoresis-assisted AFL-PDT in Actinic Keratosis","status":"COMPLETED","sponsor":"Dong-A University","startDate":"2014-06","conditions":"Actinic Keratosis","enrollment":45},{"nctId":"NCT01260987","phase":"PHASE2, PHASE3","title":"Fractional CO2 Laser Assisted Photodynamic Therapy","status":"COMPLETED","sponsor":"Bispebjerg Hospital","startDate":"2010-10","conditions":"Actinic Keratosis, Basal Cell Carcinoma","enrollment":47}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":29,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Metvix and conventional PDT","genericName":"Metvix and conventional PDT","companyName":"Galderma R&D","companyId":"galderma-r-d","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Metvix is a photosensitizing agent that accumulates in abnormal skin cells and, when activated by light in photodynamic therapy (PDT), generates reactive oxygen species to destroy lesions. Used for Actinic keratosis, Basal cell carcinoma, Bowen's disease.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}